resection of the primary tumor from mice

Evaluierung antigenspezifischer CD8+ T-Zellen während der Lymphknotenmetastasierung

Cancer immunotherapy, especially the immune checkpoint blockade (ICB), has revolutionized cancer therapy1. ICB blocks the coinhibitory immunoreceptors (such as PD-1, Tim-3, LAG-3, and TIGIT), which are highly expressed in exhausted CD8+ T cells in the tumor microenvironment (TME), leading to the reinvigoration of exhausted CD8+ T cells2. Considering the heterogeneity of exhausted CD8+ T cells, accumulating evidence revealed that tumor-specific CD8+ T cells derived from the periphery, including draining lymph node (dLN), but not in TME, mediate the efficacy of ICB3,4,5,6,7,8. Recently, TdLN derived TCF-1+TOX- tumor-specific memory CD8+ T cells (TdLN-TTSM) was confirmed to be the genuine responders to ICB which embody several functional properties of conventional memory T cells and could further expand and differentiate into progeny exhausted cells upon ICB treatment9. Altogether, these findings corroborated the importance of LN in mounting anti-tumor immunity.
Lymph node functions as a critical place in facilitating the priming and activation of tumor-specific CD8+ T cells by providing structural basis as well as biological signals10. Several types of cancer cells frequently seed sentinel lymph node (SLN, the first LN draining a primary tumor) before systematic dissemination11. The presence of SLN metastasis is linked with poor outcome in human cancer and preclinical models showed that tumor cells in TdLN could spread to distant organs through both the lymphatic vessels and blood vessels of the node12,13,14,15. SLN biopsy now represents a standard procedure to guide subsequent treatment decisions in many solid tumor types which could avoid unnecessary resection of uninvolved LN16,17. Even to the involved LN, it remains controversial whether and when surgical resection is needed as several studies have demonstrated that the removal of regional LN did not exhibit improved overall survival compared to those that received radiation or systemic therapy without regional LN resection18,19. One interpretation is that metastatic LN (mLN) with microscopic disease may retain some capacity to educate immune cells and provide some therapeutic benefits. So, it is critically important to elucidate how LN metastasis affects the anti-tumor immune response, especially the properties and functions of TdLN-TTSM.
Until now, both preclinical and clinical data have revealed some structural and cellular alterations in mLN20. However, the dynamic changes of tumor-specific CD8+ T cells during LN metastasis have not been delineated. Therefore, developing a compelling model of LN metastasis is needed for further investigation. Indeed, several studies have reported mLN mouse models through different ways14,21,22. For example, spontaneous metastasis in axillary LNs was conducted through the implantation of 4T1 breast cancer cells into the mammary fat pad22. In another study, Reticker-Flynn et al. generated melanoma cell lines with high incidence of spread from subcutaneous primary tumor to LNs through serial inoculation of tumor cells cultured from dissociated mLN tissues (nine rounds)14. Another commonly used model was prepared by the injection of tumor cells into the footpad and the metastatic loci would be formed in popliteal LN22. Notably, it is difficult to evaluate the precise timepoints of intervention because LN metastasis in these models is not always faithful.
In the present study, a murine LN metastatic model was established through the intranodal injection of B16F10-GP cells23,24, generated by CRISPR/Cas9-mediated insertion of LCMV virus glycoprotein (GP) gene sequence into the genome of B16F10 cell line9. Then, these mice were transferred with P14 cells which harbor transgenic T cell receptors (TCRs) specifically recognize the H-2Db GP33-41 epitope25,26 and the systemic and local dynamics of antigen-specific CD8+ T cells during LN metastasis could be investigated. Our experimental design provides a useful model for the study of immune responses, especially the antigen-specific CD8+ T cells during the LN metastasis which excludes the perturbation of bystander CD8+ T cells. These results would affect the clinical treatment options of whether to remove or retain the mLN and shed new light on the manipulation of mLN to achieve maximum therapeutic benefits.

Autor im Rampenlicht: Ein Modell zur Untersuchung der systemischen und lokalen Dynamik von CD8+ T-Zellen während der LN-Metastasierung

Modell der drainierenden Lymphknotenmetastasierung zur Beurteilung der Dynamik antigenspezifischer CD8+ T-Zellen während der Tumorentstehung

This protocol provides a useful reproductive model for the studies of antigen specific CD8 T-cells. They are lymph node metastasis, which excludes the participation of bystander CD8 T-cells. We try to reveal the systemic and local dynamics of antigen specific CD8 T cells They are lymph node metastasis.Recent accumulating evidence revealed that tumor specific CD8 T cells derived from the periphery, especially in tumor draining lymph node, but not in tumor microenvironment met the efficacy of immune checkpoint blockage therapy. Recently we identified this in one positive talks negative tumor sub specific memory T cells in tumor draining lymph nodes of both mice tumor models and human hepatocellular carcinoma patients which serve as general responders to immune checkpoint blockage. It is difficult to evaluate the precise time points of intubation because lymph nodes metastasis through other techniques is not always feasible.This protocol has provided an approach to precisely investigate the antigen specific CD8 T-cells immune responses. The lymph node metastasis, which excludes the participation of bystander CD8 T cells. Our experimental design provides a useful model to investigate the antigen specific CD8 T-cells, the lymph node metastasis and interactions between antigen specific CD8 T cells and other immune cells or stroma cells during lymph node metastasis.We'll try to elucidate how lymph node metastasis affects the anti-tumor immune response, especially the properties and the functions of TDR and TTSM cells. This results would affect the clinical treatment options of whether to remove or retain the MLN and show the new light on the manipulation of MLN to achieve maximum therapeutic benefits.

Resektion des Primärtumors von Mäusen

Zu Beginn tasten Sie den Primärtumor ab und stellen Sie fest, ob der Tumor einen Durchmesser von etwa fünf Millimetern hat. Um eine Tumorresektion durchzuführen, legen Sie die Maus in eine Biosicherheitswerkbank und positionieren Sie sie auf einer anatomischen Platte, die mit sauberem, saugfähigem Papier bedeckt ist. Richten Sie die Maus in Rückenlage so aus, dass ihre Längsachse parallel zum Experimentator verläuft.Desinfizieren Sie den Bauch der Maus mit einem in Povidonjod getränkten Wattebausch. Machen Sie anschließend mit einem sterilen Skalpell einen Hautschnitt in der Nähe der tumortragenden Stelle. Führen Sie die geschlossene Spitze der sterilen Pinzette in den Einschnitt ein, um den Tumor deutlich freizulegen.Entfernen Sie den Tumor und stellen Sie sicher, dass die Kapsel so intakt wie möglich bleibt. Entfernen Sie vorsichtig und vorsichtig das an den Tumor angrenzende Bindegewebe mit einer sterilen Schere.

Research

JoVE Journal

Immunology and Infection

Resection of the Primary Tumor From Mice

Draining Lymph Node Metastasis Model for Assessing the Dynamics of Antigen-Specific CD8+ T Cells During Tumorigenesis

Tumor antigen-specific CD8+ T cells from draining lymph nodes gain an accumulating importance in mounting anti-tumor immune response during tumorigenesis. ...

Forschung

Immunologie und Infektion

Ectopic Inoculation of B16F10-GP Melanoma Cells in Inguinal Region of Mice

Ektopische Inokulation von B16F10-GP-Melanomzellen in der Leistenregion von Mäusen

Adoptive Transfer of P14 T-Cells into Tumor-Bearing Mice

Adoptiver Transfer von p14-T-Zellen in tumortragende Mäuse

Intranodal Injection of B16F10-GP Cells in the Inguinal Lymph Node of Mice

Intranodale Injektion von B16F10-GP-Zellen in den Leistenlymphknoten von Mäusen